Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

被引:61
作者
Tam, Ka Ho [1 ]
Yang, Zhen Fan [1 ]
Lau, Chi Keung [1 ]
Lam, Chi Tat [1 ]
Pang, Roberta W. C. [2 ]
Poon, Ronnie T. P. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Med, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China
关键词
mTOR; p53; RAD001; HCC; Chemosensitivity; Chemoresistance; RANDOMIZED CONTROLLED-TRIAL; MAMMALIAN TARGET; CANCER; CHEMOTHERAPY; CELLS; AKT;
D O I
10.1016/j.canlet.2008.08.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 27 条
  • [1] Aft RL, 2003, CANCER RES, V63, P5496
  • [2] AMATO RJ, 2006, P ASCO ANN M
  • [3] Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma
    Barbare, JC
    Bouché, O
    Bonnetain, F
    Raoul, JL
    Rongier, P
    Abergel, A
    Boige, V
    Denis, B
    Blanchi, A
    Pariente, A
    Milan, C
    Bedenne, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4338 - 4346
  • [4] The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
    Beuvink, I
    Boulay, A
    Fumagalli, S
    Zilbermann, F
    Ruetz, S
    O'Reilly, T
    Natt, F
    Hall, J
    Lane, HA
    Thomas, G
    [J]. CELL, 2005, 120 (06) : 747 - 759
  • [5] Primary liver cancer:: Worldwide incidence and trends
    Bosch, FX
    Ribes, J
    Díaz, M
    Cléries, R
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S5 - S16
  • [6] Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
    Calvisi, DF
    Ladu, S
    Gorden, A
    Farina, M
    Conner, EA
    Lee, JS
    Factor, VM
    Thorgeirsson, SS
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : 1117 - 1128
  • [7] Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells
    Chi, Tian-Yi
    Chen, George G.
    Ho, Lok-Kee
    Lai, Paul B. S.
    [J]. CANCER CELL INTERNATIONAL, 2005, 5 (1)
  • [8] Current development of mTOR inhibitors as anticancer agents
    Faivre, Sandrine
    Kroemer, Guido
    Raymond, Eric
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 671 - 688
  • [9] Grünwald V, 2002, CANCER RES, V62, P6141
  • [10] HUDES G, 2006, P ASCO ANN M